Skip to main content Skip to footer

Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw

December 2022

SDCEP is conducting a review of the context of this guidance (regulations, legislation, trends in working practices, experience and evidence) to inform the extent of any updating required.

Feedback from practitioners and GDG members has not to date identified any concerns about the key recommendations. However, we are aware of newer studies reporting on MRONJ incidence and on other drugs associated with MRONJ and work is ongoing to determine whether there are implications for the guidance.

Partner programmes